ArticleTropical medicine and health2026
Antileishmanial potential of polar fractions from Amaranthus blitoides S. Watson, Caucalis platycarpos L., and Cistanche flava (C.A.Mey.) Korsh.: evidence from in vitro and in vivo studies.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous leishmaniasis (CL) is recognized by the World Health Organization (WHO) as a research priority, yet its treatment remains challenging. CL lesions arise from complex interactions between the parasite and host immunity, where excessive inflammation can delay healing. Given the anti-inflammatory and immunomodulatory properties of medicinal plants, this study evaluated the effects of polar fractions from methanolic extracts of Amaranthus blitoides S. Watson, Caucalis platycarpos L., Cistanche flava (C.A.Mey.) Korsh., and their mixtures on CL caused by Leishmania major.
methodsIn vitro, the antileishmanial activity of polar fractions against L. major promastigotes and their cytotoxicity on RAW 264.7 macrophages were assessed using flow cytometry and MTT assay, respectively. In vivo, female BALB/c mice infected with L. major were treated with polar fractions. Lesion size was monitored weekly, and at the end of treatment, parasite load at lesion margins and seven liver biochemical parameters in serum were measured.
resultsPolar fractions exhibited mild-to-moderate antileishmanial effects on promastigotes without significant cytotoxicity to macrophages. In vivo, treatment with 20 mg/kg C. platycarpos, 20 mg/kg C. flava, and 80 mg/kg of the mixture significantly reduced lesion size compared to controls. Clinical observations also indicated reduced local inflammation in these groups. Parasite load remained detectable across all groups, and liver biochemical parameters did not differ significantly from the negative control.
conclusionPolar fractions of the studied plants demonstrated safety and therapeutic promise, supporting their potential as adjunctive candidates for further investigation in the management of CL caused by L. major.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.